Radioimmunotherapies for non-Hodgkin lymphoma

The associated guideline recommends Based on the evidence, the use of 131 90 that the use of 90Y-ibritumomab tiuxetan be I-tositumomab and Y-ibritumomab may be prioritized for patients with follicular NHL treatment options for patients with refractory or refractory to chemotherapy and rituximab, and relapsed NHL. [...] Most of the information provided on inclusion and exclusion included studies were small, single-arm studies, criteria of the individual studies, it is unfeasible and the authors failed to systematically assess to comment on the generalizability of these internal and external validity. [...] Most of the patients had follicular clinical trials of the efficacy of using lymphoma, but it is unknown whether similar 90Y-ibritumomab tiuxetan in the treatment of results would be expected if the entire recurrent NHL. [...] The purpose of PFS was longer in the 90Y-ibritumomab tiuxetan this comparison was to determine the consolidation group than in the control group contribution of radioisotope-labelling to the (HR 0.383; 95% CI 0.235 to 0.625). [...] The authors of the study insufficient to determine the duration of concluded that the use of 90Y-ibritumomab 8 Radioimmunotherapies for Non-Hodgkin Lymphoma: Systematic Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines tiuxetan produced high response rates and treatments included 131I-tositumomab alone, durable remissions in patients with previously rituximab alone (four-dose or